Existing drug may treat triple-negative breast cancer

| October 9, 2018

article image
The existing drug estradiol can inhibit tumor growth in a subtype of triple-negative breast cancer. The researchers may soon test the repurposed drug in phase II clinical trial. Triple-negative breast cancer is an aggressive form of breast cancer wherein tumors lack expression of three proteins. The three are the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2).

Spotlight

Ciron Drugs And Pharmaceuticals Private Limited

Established in 1966, the Ciron Group of Companies has through its pioneering efforts emerged as a reputed manufacturer & exporter of pharmaceutical products such as injections, eye,ear and nasal drops, syrups,injections, ointments, powders, tablets and capsules,. For over four decades, the company has grown from strength to strength into the leading position in the health care industry.

OTHER ARTICLES

Enabling Active Pharma Ingredients for Batch Balancing and Integration to SAP EWM

Article | April 6, 2020

Batch and its Classification system are two most potent weapons used in Chemical, Pharma or Medical life science industry to record the potency of a batch or technically called as Active Pharma Ingredients(API). These material consist of one or more active ingredients, concentrates, carrier materials, or impurities, and so on. The potency of the active ingredients varies from batch to batch. The active ingredient is the substance of greatest interest in the bill of materials, the proportion of which may vary from batch to batch. Therefore, during creation of a process order, the system must be able to select and adjust the batches needed to obtain the required amount of active ingredient. Take an example of a drug hydroxychloroquine which is used as potent weapon to fight COVID-19. This drug is manufactured by using API, however, the Potency of this API material vary from batch to batch. To map this kind of requirement in SAP ERP, SAP calls it as Material Quantity Calculation.

Read More

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | April 6, 2020

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More

Clinical Supply Availability & Speed to Study Start-Up

Article | April 6, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | April 6, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

Spotlight

Ciron Drugs And Pharmaceuticals Private Limited

Established in 1966, the Ciron Group of Companies has through its pioneering efforts emerged as a reputed manufacturer & exporter of pharmaceutical products such as injections, eye,ear and nasal drops, syrups,injections, ointments, powders, tablets and capsules,. For over four decades, the company has grown from strength to strength into the leading position in the health care industry.

Events